Clinical and Experimental Nephrology

, Volume 18, Issue 3, pp 499–506 | Cite as

Low serum testosterone is associated with atherosclerosis in postmenopausal women undergoing hemodialysis

  • Nobuaki Shiraki
  • Ayumu Nakashima
  • Shigehiro Doi
  • Juan Jesús Carrero
  • Naoko Sugiya
  • Toshinori Ueno
  • Peter Stenvinkel
  • Nobuoki Kohno
  • Takao Masaki
Original Article

Abstract

Background

Low serum testosterone levels have been recently linked to endothelial dysfunction, arterial stiffness, and worse outcomes in male hemodialysis patients. We tested the hypothesis that low serum testosterone levels are also associated with atherosclerosis risk factors in postmenopausal women undergoing hemodialysis.

Methods

We measured serum testosterone in 115 confirmed postmenopausal ethnically Japanese women undergoing hemodialysis with mean age of 68.1 ± 10.6 years and median dialysis vintage of 73 months. The severity of atherosclerosis was evaluated by carotid intima–media thickness (cIMT) and cardio–ankle vascular index (CAVI). In addition, we also included a control cohort of 32 age-matched postmenopausal women without chronic kidney disease.

Results

Serum testosterone was significantly lower in women undergoing hemodialysis than in age-matched controls. Women undergoing hemodialysis who had undetectable testosterone concentration presented higher cIMT and higher CAVI than women undergoing hemodialysis with testosterone concentration above detection limits (P < 0.05 for all). Multiple logistic regression analyses confirmed the independence of these associations.

Conclusion

Serum testosterone levels in postmenopausal women undergoing hemodialysis are abnormally low and associated with features of atherosclerosis.

Keywords

Testosterone Atherosclerosis Hemodialysis Postmenopausal woman 

References

  1. 1.
    Carrero JJ. Gender differences in chronic kidney disease: underpinnings and therapeutic implications. Kidney Blood Press Res. 2010;33:383–92.PubMedCrossRefGoogle Scholar
  2. 2.
    Carrero JJ, Qureshi AR, Nakashima A, et al. Prevalence and clinical implications of testosterone deficiency in men with end-stage renal disease. Nephrol Dial Transplant. 2011;26:184–90.PubMedCrossRefGoogle Scholar
  3. 3.
    Carrero JJ, Stenvinkel P. The vulnerable man: impact of testosterone deficiency on the uraemic phenotype. Nephrol Dial Transplant. 2012;27:4030–41.PubMedCrossRefGoogle Scholar
  4. 4.
    Basaria S, Dobs AS. Hypogonadism and androgen replacement therapy in elderly men. Am J Med. 2001;110:563–72.PubMedCrossRefGoogle Scholar
  5. 5.
    Maggio M, Basaria S. Welcoming low testosterone as a cardiovascular risk factor. Int J Impot Res. 2009;21:261–4.PubMedCentralPubMedCrossRefGoogle Scholar
  6. 6.
    Alexandersen P, Haarbo J, Christiansen C. The relationship of natural androgens to coronary heart disease in males: a review. Atherosclerosis. 1996;125:1–13.PubMedCrossRefGoogle Scholar
  7. 7.
    Shapiro J, Christiana J, Frishman WH. Testosterone and other anabolic steroids as cardiovascular drugs. Am J Ther. 1999;6:167–74.PubMedCrossRefGoogle Scholar
  8. 8.
    Jones RD, Pugh PJ, Jones TH, et al. The vasodilatory action of testosterone: a potassium-channel opening or a calcium antagonistic action? Br J Pharmacol. 2003;138:733–44.PubMedCentralPubMedCrossRefGoogle Scholar
  9. 9.
    Foresta C, Caretta N, Lana A, et al. Reduced number of circulating endothelial progenitor cells in hypogonadal men. J Clin Endocrinol Metab. 2006;91:4599–602.PubMedCrossRefGoogle Scholar
  10. 10.
    Dalia S, Fortune K, Anat J, et al. Effects of gonadal steroids and their antagonists on DNA synthesis in human vascular cells. Hypertension. 1998;32:39–45.Google Scholar
  11. 11.
    Carrero JJ, Bárány P, Yilmaz MI, et al. Testosterone deficiency is a cause of anaemia and reduced responsiveness to erythropoiesis-stimulating agents in men with chronic kidney disease. Nephrol Dial Transplant. 2012;27:709–15.PubMedCrossRefGoogle Scholar
  12. 12.
    Cigarran S, Pousa M, Castro MJ, et al. (2013) Endogenous testosterone, muscle strength and fat-free mass in men with chronic kidney disease. J Ren Nutr.Google Scholar
  13. 13.
    Yilmaz MI, Sonmez A, Qureshi AR, et al. Endogenous testosterone, endothelial dysfunction, and cardiovascular events in men with nondialysis chronic kidney disease. Clin J Am Soc Nephrol. 2011;6:1617–25.PubMedCrossRefGoogle Scholar
  14. 14.
    Kyriazis J, Tzanakis I, Stylianu K, et al. Low serum testosterone, arterial stiffness and mortality in male hemodialysis patients. Nephrol Dial Transplant. 2011;26:2971–7.PubMedCrossRefGoogle Scholar
  15. 15.
    Laughlin GA, Goodell V, Barrett-Connor E. Extremes of endogenous testosterone are associated with increased risk of incident coronary events in older women. J Clin Endocrinol Metab. 2010;95:740–7.PubMedCentralPubMedCrossRefGoogle Scholar
  16. 16.
    Sievers C, Klotsche J, Pieper L, et al. Low testosterone levels predict all-cause mortality and cardiovascular events in women: a prospective cohort study in German primary care patients. Eur J Endocrinol. 2010;163:699–708.PubMedCrossRefGoogle Scholar
  17. 17.
    Creatsa M, Armeni E, Stamatelopoulos K, et al. Circulating androgen levels are associated with subclinical atherosclerosis and arterial stiffness in healthy recently menopausal women. Metabolism. 2012;61:193–201.PubMedCrossRefGoogle Scholar
  18. 18.
    Patel SM, Ratcliffe SJ, Reilly MP, et al. Higher serum testosterone concentration in older women is associated with insulin resistance, metabolic syndrome, and cardiovascular disease. J Clin Endocrinol Metab. 2009;94:4776–84.PubMedCentralPubMedCrossRefGoogle Scholar
  19. 19.
    McKinlay SM, Brambilla DJ, Posner JG. The normal menopause transition. Maturitas. 1992;14:103–15.PubMedCrossRefGoogle Scholar
  20. 20.
    Kramer HM, Curhan GC, Singh A, et al. Permanent cessation of menses and postmenopausal hormone use in dialysis-dependent women: the HELP study. Am J Kidney Dis. 2003;41:643–50.PubMedCrossRefGoogle Scholar
  21. 21.
    Wendelhag I, Wiklund O, Wikstrand J. Atherosclerotic changes in the femoral and carotid arteries in familial hypercholesterolemia. Ultrasonographic assessment of intima-media thickness and plaque occurrence. Arterioscler Thromb. 1993;13:1404–11.PubMedCrossRefGoogle Scholar
  22. 22.
    Shirai K, Utino J, Otsuka K, et al. A novel blood pressure-independent arterial wall stiffness parameter; cardio-ankle vascular index (CAVI). J Atheroscler Thromb. 2006;13:101–7.PubMedCrossRefGoogle Scholar
  23. 23.
    Zoungas S, Cameron JD, Kerr PG, et al. Association of carotid intima-medial thickness and indices of arterial stiffness with cardiovascular disease outcomes in CKD. Am J Kidney Dis. 2007;50:622–30.PubMedCrossRefGoogle Scholar
  24. 24.
    Shoji T, Maekawa K, Emoto M, et al. Arterial stiffness predicts cardiovascular death independent of arterial thickness in a cohort of hemodialysis patients. Atherosclerosis. 2010;210:145–9.PubMedCrossRefGoogle Scholar
  25. 25.
    Payne RB, Little AJ, Williams RB, et al. Interpretation of serum calcium in patients with abnormal serum proteins. Br Med J. 1973;4:643–6.PubMedCentralPubMedCrossRefGoogle Scholar
  26. 26.
    Singh AB, Norris K, Modi N, et al. Pharmacokinetics of a transdermal testosterone system in men with end stage renal disease receiving maintenance hemodialysis and healthy hypogonadal men. J Clin Endocrinol Metab. 2001;86:2437–45.PubMedGoogle Scholar
  27. 27.
    Schmidt A, Luger A, Hörl WH. Sexual hormone abnormalities in male patients with renal failure. Nephrol Dial Transplant. 2002;17:368–71.PubMedCrossRefGoogle Scholar
  28. 28.
    Carrero JJ, Kyriazis J, Sonmez A, et al. Prolactin levels, endothelial dysfunction, and the risk of cardiovascular events and mortality in patients with CKD. Clin J Am Soc Nephrol. 2012;7:207–15.PubMedCentralPubMedCrossRefGoogle Scholar
  29. 29.
    Strippoli GF. Collaborative depression and sexual dysfunction (CDS) in hemodialysis working group. Sexual dysfunction in women with ESRD requiring hemodialysis. Clin J Am Soc Nephrol. 2012;7:974–81.PubMedCentralPubMedCrossRefGoogle Scholar
  30. 30.
    Hladunewich M, Hercz AE, Keunen J, et al. Pregnancy in end stage renal disease. Semin Dial. 2011;24:634–9.PubMedCrossRefGoogle Scholar
  31. 31.
    Golden SH, Maguire A, Ding J, et al. Endogenous postmenopausal hormones and carotid atherosclerosis: a case-control study of the atherosclerosis risk in communities cohort. Am J Epidemiol. 2002;155:437–45.PubMedCrossRefGoogle Scholar
  32. 32.
    Montalcini T, Gorgone G, Gazzaruso C, et al. Role of endogenous androgens on carotid atherosclerosis in non-obese postmenopausal women. Nutr Metab Cardiovasc Dis. 2007;17:705–11.PubMedCrossRefGoogle Scholar
  33. 33.
    Bernini GP, Sgro’ M, Barlascini CO, et al. Endogenous androgens and carotid intimal-medial thickness in women. J Clin Endocrinol Metab. 1999;84:2008–12.PubMedCrossRefGoogle Scholar
  34. 34.
    Yaron M, Greenman Y, Rosenfeld JB, et al. Effect of testosterone replacement therapy on arterial stiffness in older hypogonadal men. Eur J Endocrinol. 2009;160:839–46.PubMedCrossRefGoogle Scholar
  35. 35.
    Dockery F, Bulpitt CJ, Donaldson M, et al. The relationship between androgens and arterial stiffness in older men. J Am Geriatr Soc. 2003;51:1627–32.PubMedCrossRefGoogle Scholar
  36. 36.
    Hougaku H, Fleg JL, Najjar SS, et al. Relationship between androgenic hormones and arterial stiffness, based on longitudinal hormone measurements. Am J Physiol Endocrinol Metab. 2006;290:E234–42.PubMedCrossRefGoogle Scholar
  37. 37.
    Montalcini T, Gorgone G, Gazzaruso C, et al. Endogenous testosterone and endothelial function in postmenopausal women. Coron Artery Dis. 2007;18:9–13.PubMedCrossRefGoogle Scholar
  38. 38.
    Izuhara M, Shioji K, Kadota S, et al. Relationship of cardio-ankle vascular index (CAVI) to carotid and coronary arteriosclerosis. Circ J. 2008;72:1762–7.PubMedCrossRefGoogle Scholar
  39. 39.
    Carrero JJ, Stenvinkel P, Cuppari L, et al. Etiology of the protein-energy wasting syndrome in chronic kidney disease: a consensus statement from the International Society of Renal Nutrition and Metabolism (ISRNM). J Ren Nutr. 2013;23:77–90.PubMedCrossRefGoogle Scholar
  40. 40.
    Nettleship JE, Jones TH, Channer KS, et al. Physiological testosterone replacement therapy attenuates fatty streak formation and improves high-density lipoprotein cholesterol in the Tfm mouse: an effect that is independent of the classic androgen receptor. Circulation. 2007;116:2427–34.PubMedCrossRefGoogle Scholar
  41. 41.
    Braunstein GD, Johnson BD, Stanczyk FZ, et al. Relations between endogenous androgens and estrogens in postmenopausal women with suspected ischemic heart disease. J Clin Endocrinol Metab. 2008;93:4268–75.PubMedCentralPubMedCrossRefGoogle Scholar
  42. 42.
    Foresta C, Zuccarello D, De Toni L, et al. Androgens stimulate endothelial progenitor cells through an androgen receptor-mediated pathway. Clin Endocrinol (Oxf). 2008;68:284–9.Google Scholar
  43. 43.
    Liu D, Dillon JS. Dehydroepiandrosterone stimulates nitric oxide release in vascular endothelial cells: evidence for a cell surface receptor. Steroids. 2004;69:279–89.PubMedCrossRefGoogle Scholar
  44. 44.
    Webb CM, Elkington AG, Kraidly MM, et al. Effects of oral testosterone treatment on myocardial perfusion and vascular function in men with low plasma testosterone and coronary heart disease. Am J Cardiol. 2008;101:618–24.PubMedCentralPubMedCrossRefGoogle Scholar
  45. 45.
    Malkin CJ, Jones RD, Jones TH, et al. Effect of testosterone on ex vivo vascular reactivity in man. Clin Sci (Lond). 2006;111:265–74.CrossRefGoogle Scholar
  46. 46.
    Ros S, Carrero JJ. Endocrine alterations and cardiovascular risk in CKD: is there a link? Nefrologia. 2013;33:181–7.PubMedGoogle Scholar

Copyright information

© Japanese Society of Nephrology 2013

Authors and Affiliations

  • Nobuaki Shiraki
    • 1
  • Ayumu Nakashima
    • 1
    • 2
  • Shigehiro Doi
    • 1
  • Juan Jesús Carrero
    • 4
    • 5
  • Naoko Sugiya
    • 6
  • Toshinori Ueno
    • 1
  • Peter Stenvinkel
    • 4
  • Nobuoki Kohno
    • 3
  • Takao Masaki
    • 1
  1. 1.Department of NephrologyHiroshima University HospitalHiroshimaJapan
  2. 2.Department of Regenerative MedicineHiroshima University HospitalHiroshimaJapan
  3. 3.Department of Molecular and Internal Medicine, Graduate School of Biomedical SciencesHiroshima UniversityHiroshimaJapan
  4. 4.Divisions of Renal Medicine and Baxter Novum, Department of Clinical Science, Intervention and TechnologyKarolinska InstitutetStockholmSweden
  5. 5.Centre for Molecular MedicineKarolinska InstitutetStockholmSweden
  6. 6.Department of NephrologyKure Kyosai HospitalKureJapan

Personalised recommendations